ESTIMATING THE PUBLIC HEALTH AND ECONOMIC BENEFIT ASSOCIATED WITH THE IMPLEMENTATION OF AN ADULT RSV NATIONAL IMMUNISATION PROGRAMME IN ENGLAND
Author(s)
Jack Said, MSc1, Rebecca Butfield, MPH1, Andrew Vyse, PhD1, Erin Quinn, BSc2, Mary MacKinnon, BSc2, Reiko Sato, PhD3.
1Pfizer Ltd, Tadworth, United Kingdom, 2Avalere Health, Washington, DC, USA, 3Pfizer Inc, Collegeville, PA, USA.
1Pfizer Ltd, Tadworth, United Kingdom, 2Avalere Health, Washington, DC, USA, 3Pfizer Inc, Collegeville, PA, USA.
OBJECTIVES: England’s adult respiratory syncytial virus (RSV) national immunisation programme (NIP) began in September 2024, initially targeting adults aged 75-79 years. By April 2026, eligibility expanded to include adults aged ≥80 years and care home residents. Based on recent advice from the Joint Committee on Vaccination and Immunisation (JCVI), additional expansion to high-risk adults aged 65-74 years is anticipated. We aim to estimate the public health and economic benefit already realised by the NIP in England, as well as potential future impact.
METHODS: A static Markov-type model was developed to estimate outcomes associated with RSV among adults and the impact of immunisation over a 5-year horizon. Model inputs, estimated from UK-specific data, included: population characteristics, setting-specific incidence of RSV (hospital, accident and emergency [A&E], general practitioner [GP]), case-fatality, vaccine characteristics, and medical care costs. Effectiveness was derived from real-world and clinical trial data. Years 1-2 represent the 2024/25 NIP (uptake: Y1, 58.9%; Y2, 63.6%); for years 3-5, the NIP was assumed to include high-risk adults aged 65-74 years (uptake: Y3-Y5, 40%) and all adults aged ≥75 years (uptake: Y3, 63.6%; Y4-Y5, 70%).
RESULTS: Since implementation, the RSV adult NIP has averted an estimated 4,203 hospitalisations, 3,449 A&E encounters, 29,616 GP visits, and 384 RSV-associated deaths, compared to no vaccination. Accordingly, an estimated £24M healthcare costs to the NHS were averted in 2 years. With an expanded NIP, it is estimated that 25,755 hospitalisations, 18,558 A&E encounters, 86,697 GP visits, and 3,045 deaths would be averted over 5 years, with total healthcare savings of £125M.
CONCLUSIONS: Since implementation, the RSV adult NIP is estimated to have averted a substantial number of RSV-related clinical outcomes and yielded considerable reductions in healthcare costs. The public health and economic benefits of the NIP are expected to rise in the following years following the expansion of the eligible cohort.
METHODS: A static Markov-type model was developed to estimate outcomes associated with RSV among adults and the impact of immunisation over a 5-year horizon. Model inputs, estimated from UK-specific data, included: population characteristics, setting-specific incidence of RSV (hospital, accident and emergency [A&E], general practitioner [GP]), case-fatality, vaccine characteristics, and medical care costs. Effectiveness was derived from real-world and clinical trial data. Years 1-2 represent the 2024/25 NIP (uptake: Y1, 58.9%; Y2, 63.6%); for years 3-5, the NIP was assumed to include high-risk adults aged 65-74 years (uptake: Y3-Y5, 40%) and all adults aged ≥75 years (uptake: Y3, 63.6%; Y4-Y5, 70%).
RESULTS: Since implementation, the RSV adult NIP has averted an estimated 4,203 hospitalisations, 3,449 A&E encounters, 29,616 GP visits, and 384 RSV-associated deaths, compared to no vaccination. Accordingly, an estimated £24M healthcare costs to the NHS were averted in 2 years. With an expanded NIP, it is estimated that 25,755 hospitalisations, 18,558 A&E encounters, 86,697 GP visits, and 3,045 deaths would be averted over 5 years, with total healthcare savings of £125M.
CONCLUSIONS: Since implementation, the RSV adult NIP is estimated to have averted a substantial number of RSV-related clinical outcomes and yielded considerable reductions in healthcare costs. The public health and economic benefits of the NIP are expected to rise in the following years following the expansion of the eligible cohort.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE138
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines